Awọn ọja adayeba 8 lati ja rirẹ

Awọn ọja adayeba 8 lati ja rirẹ

Awọn ọja adayeba 8 lati ja rirẹ
Boya ti ara tabi aifọkanbalẹ, rirẹ nigbagbogbo n waye lati awọn ihuwasi igbesi aye ti ko dara tabi awọn iṣoro ilera bii aini oorun, aito ounjẹ, isanraju, awọn nkan ti ara korira, alakan, overtraining tabi eyikeyi awọn akoran ni gbogbogbo. . Lati ṣe atunṣe eyi, nigbagbogbo o jẹ dandan lati koju orisun iṣoro naa, ṣugbọn o ṣee ṣe lati lo awọn ọja ilera adayeba ni afikun. Aworan ti 5 ti awọn ọja ti a fihan.

Valerian fun dara orun

Valerian ati oorun ti ni asopọ pẹkipẹki fun awọn ọdunrun ọdun. Tẹlẹ ni Greece atijọ, awọn dokita Hippocrates ati Galen ṣeduro lilo rẹ lodi si insomnia. Ni Aringbungbun ogoro, herbalists ri o bi a pipe tranquilizer. Nígbà Ogun Àgbáyé Kìíní, ó tiẹ̀ wọ́pọ̀ gan-an láti rí i nínú àpò àwọn ọmọ ogun tí wọ́n lò ó láti mú kí ìdààmú ọkàn tí wọ́n ń ró bọ́ǹbù ń fà. Pelu ohun gbogbo, ati iyalenu bi o ṣe le dabi, iwadi iwosan ti ṣi kuna lati ṣe afihan ipa rẹ lodi si aisun oorun. Diẹ ninu awọn ijinlẹ ṣe akiyesi rilara ti oorun ti ilọsiwaju1,2 bakanna bi idinku ninu rirẹ3, ṣugbọn awọn iwoye wọnyi ko ni ifọwọsi nipasẹ eyikeyi awọn ibeere idi (akoko lati sun oorun, iye akoko oorun, nọmba awọn ijidide lakoko alẹ, bbl).

Commission E, ESCOP ati WHO sibẹsibẹ mọ lilo rẹ lati ṣe itọju awọn rudurudu oorun ati, nitori naa, rirẹ ti o yọrisi rẹ. A le mu Valerian ni inu awọn iṣẹju 30 ṣaaju akoko sisun: fi 2 si 3 g ti gbongbo ti o gbẹ fun iṣẹju 5 si 10 ni 15 cl ti omi farabale.

awọn orisun

Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Fernández-San-Martín MI, Masa-Font R, et al. Sleep Med. 2010 Jun;11(6):505-11. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Fernández-San-Martín MI, Masa-Font R, et al. Sleep Med. 2010 Jun;11(6):505-11. Bent S, Padula A, Moore D, et al. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006 Dec;119(12):1005-12. The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). Barton DL, Atherton PJ, et al. J Support Oncol. 2011 Jan-Feb;9(1):24-31.

Fi a Reply